Key clinical point: Bone-modifying agents (BMAs) are overused in the real world in patients with metastatic castration-sensitive prostate cancer (mCSPC).
Major finding: Receipt of BMAs was reported in 23.6% of patients within 180 days of diagnosis. The proportion of patients receiving BMAs within 180 days increased from 17.3% during 2007-2009 to 28.1% during 2012-2015.
Study details: A retrospective study of 2,627 patients with stage IV prostate cancer from the Surveillance, Epidemiology, and End Results-Medicare database, diagnosed between 2007 and 2015. Patients receiving BMAs before the diagnosis or with a history of hypercalcemia, osteoporosis, osteopenia, or bone fracture were not included.
Disclosures: This study was supported by the National Cancer Institute at the National Institutes of Health. The authors received awards, personal/consulting/advisory fees, grants, nonfinancial support, and/or research funding from various sources. Some authors reported stock ownerships in various companies.
Source: Mitchell AP et al. J Natl Cancer Inst. 2021 Oct 1. doi: 10.1093/jnci/djab196 .